The independent source for health policy research, polling, and news.
161-180 of 1,326 results
A Supreme Court ruling restricting federal power will likely have seismic ramifications for health policy. A flood of litigation — with plaintiffs like small businesses, drugmakers, and hospitals challenging regulations they say are too expensive or burdensome and not authorized by law — could leave the country with a patchwork of disparate health regulations.
A debate marked by President Joe Biden’s faltering performance featured clashes over insulin costs, inflation, abortion, immigration, and Jan. 6.
The Supreme Court has dismissed a challenge to the FDA’s approval of the abortion pill mifepristone, ruling unanimously that the anti-abortion doctor group that filed the suit lacked standing. But abortion opponents are expected to pursue other strategies to ban or restrict the medication. Meanwhile, the Biden administration moves to stop the inclusion of medical debt on individual credit reports, and former President Donald Trump tries to claim credit for $35 insulin. Anna Edney of Bloomberg News, Rachana Pradhan of KFF Health News, and Emmarie Huetteman of KFF Health News join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF president and CEO Drew Altman about KFF’s new “Health Policy 101” primer.
President Joe Biden is campaigning for reelection on his efforts to cut costs for Medicare patients at the pharmacy counter. But independent pharmacists say one strategy makes it unaffordable for them to keep some brand-name medicines in stock.
KFF Health News gives readers a chance to comment on a recent batch of stories.
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss topical stories. Here’s a collection of their appearances.
June is when the Supreme Court typically issues rulings in the major cases it hears during that year’s term. This year, those interested in health policy are awaiting decisions in two abortion-related cases and one that could reshuffle the way health policies (and all other federal policies) are made. In this special episode, KFF’s Laurie Sobel, associate director for women’s health policy, joins Julie Rovner for a review of the cases and a preview of how the court might rule.
A disconnect between two federal programs meant to help keep hospitals afloat discourages struggling rural facilities from accepting the aid.
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
KFF Health News and California Healthline staffers made the rounds on national and local media in the last couple of weeks to discuss topical stories. Here’s a collection of their appearances.
As billions of dollars from settlements with opioid manufacturers and distributors go to state and local governments, efforts to reduce the epidemic’s harm can be hamstrung by drug paraphernalia laws. Health authorities say distributing clean syringes to users can save lives, but in states like Pennsylvania, it may be illegal.
A decade after Congress told the FDA to expedite the approval of more effective sunscreens, the federal government still has not approved sunscreen ingredients that are safely being used around the world. Meanwhile, skin cancer is the nation’s most common cancer.
The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose — which earns it an additional $180,000 a year per patient.
A six-week abortion ban took effect in Florida this week, dramatically restricting access to the procedure not just in the nation’s third-most-populous state but across the South. Patients from states with even more restrictive bans had been flooding in since the overturn of Roe v. Wade in 2022. Meanwhile, the CEO of the health behemoth UnitedHealth Group appeared before committees in both the House and Senate, where lawmakers grilled him about the February cyberattack on subsidiary Change Healthcare and how its ramifications are being felt months later. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Rachana Pradhan of KFF Health News join KFF Health News’ Julie Rovner to discuss these stories and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
KFF Health News and California Healthline staff made the rounds on national and local media over the past two weeks to discuss recent stories. Here’s a collection of their appearances.
KFF Health News staff made the rounds on state and local media in recent weeks to discuss stories they and their colleagues reported. Here’s a collection of their appearances.
Researchers at the University of Montana have pitched in to develop a more effective vaccine in the fight against an ancient disease that still kills an estimated 1.6 million people a year worldwide.
Facing widening racial disparities in overdose deaths, Philadelphia officials are sending workers and volunteers to knock on doors across the city, aiming to equip households with naloxone and other drug overdose prevention supplies. City officials hope a proactive approach will normalize naloxone as an everyday item in people’s medicine cabinets and prevent overdoses, especially among Black residents.
© 2026 KFF